{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.8","upperLimit":"89.1","value":"63.6"},{"groupId":"OG001","lowerLimit":"6.8","upperLimit":"93.2","value":"50.0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"52.2","value":"0"},{"groupId":"OG003","lowerLimit":"23.2","upperLimit":"65.5","value":"43.5"},{"groupId":"OG004","lowerLimit":"18.4","upperLimit":"90.1","value":"57.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"The ORR is defined as percentage of participants with best overall response of complete remission/response (CR) or partial remission/response (PR) based on investigator's assessment. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR is complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of the affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel; and PR is a 50 % or greater reduction in the size of all lymphomatous lesions as determined by computed tomography (CT) or magnetic resonance imaging (MRI) measurements of tumor volume, which was maintained for at least 3 weeks following completion of a cycle of tabelecleucel. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR is clearance of EBV without subsequent development of EBV+ LPD; and PR is at least a 10-fold decrease in EBV DNA levels.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with EBV+ PTLD following HCT who were R/R to rituximab received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)"},{"description":"Participants with EBV+PTLD following SOT who were R/R to rituximab and chemotherapy received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)"},{"description":"Participants with EBV+ following LMS received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"EBV+ LMS (Tab-cel Only)"},{"description":"Participants with EBV+PTLD following HCT who were R/R to rituximab or rituximab naive received donor-derived EBV-CTL on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)"},{"description":"Participants with EBV+ following viremia received donor-derived EBV-CTLs on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"EBV+ Viremia (EBV-CTLs Only)"}],"paramType":"NUMBER","populationDescription":"Full analysis set included all participants who received at least one dose of study treatment (tabelecleucel or EBV-CTLs). Results from arms with \\<= 3 participants (as shown in the participant flow) are excluded due to the low numbers of participants; these low numbers pose a risk for participant re-identification in these rare indications of this single center study.","reportingStatus":"POSTED","timeFrame":"From Day 1 through 251.1 months after Day 1 dose","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}